Trial reportNature2025
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.
Erratum issuedAbstract readClinical Trial, Phase IClinical Trial, Phase II
In one paragraph
Trial report in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 88 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 1 synthesis or guideline pooled it.
- GDF-15 as a biomarker for diagnosis and prognosis of lung cancer: a meta-analysis.Frontiers in oncology · 2025Pooled it
- Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.Journal of hematology & oncology · 2026Trial
- Targeting Phosphatidylserine in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas: A Phase 2 Trial of Bavituximab Plus Pembrolizumab with Biomarker-Correlated Outcomes.Current oncology (Toronto, Ont.) · 2026Trial
- Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial).Alimentary pharmacology & therapeutics · 2026Trial
- First-in-Human Study to Evaluate the Safety and Efficacy of Anti-GDF15 Antibody AZD8853 in Patients with Advanced/Metastatic Solid Tumors.Cancer research communications · 2025Trial
- Review
- The causes of cachexia: key signals and the brain.Nature reviews. Endocrinology · 2026Review
- Association of Cachexia-Related Status With Treatment Outcomes in Advanced Gastric Cancer Receiving First-Line Therapy With or Without Nivolumab.Journal of gastrointestinal cancer · 2026Article
- Tumour GDF-15 Expression and Clinical Outcomes in Intermediate-Risk Metastatic Clear-Cell Renal Cell Carcinoma Treated with Second-Line Nivolumab.Current oncology (Toronto, Ont.) · 2026Article
- Nanobody-based characterization of Galectin-13 reveals immunomodulatory and tumor-promoting functions.The Journal of biological chemistry · 2026Article
- Therapeutic Gfral silencing via antisense oligonucleotides ameliorates cancer-associated cachexia and extends survival in tumor-bearing mice.Cell reports. Medicine · 2026Article
- Lethal clinical outcome and immune desert contexture in refractory gastric cancer harboring CCNE1 amplification and overexpression.British journal of cancer · 2026Article
- GDF15: A Hijacked Metabo-Hormone Orchestrating Cachexia and Immunosuppression in Cancer.Biomolecules · 2026Review
- Targeting the CAF-GDF15 axis attenuates AKT-mediated mitochondrial rewiring and chemoradiation resistance in esophageal adenocarcinoma.Journal of experimental & clinical cancer research : CR · 2026Article
- Advancing Cancer Cachexia Drug Development: Leveraging Biomarkers and Functional Endpoints to Optimize Trial Design.Cancer reports (Hoboken, N.J.) · 2026Review
- Longitudinal single-cell and TCR repertoire profiling characterizes clonal entrapment in patients with pMMR/MSS locally advanced rectal cancer.Cell discovery · 2026Article
- Multidrug resistance in cancer: current understandings and future perspective.Molecular biomedicine · 2026Review
- Multimodal blood based proteomic profiling reveals insights into mechanisms of immunotherapy resistance.Nature communications · 2026Article
- Article
- Multi-omics integration model of exosome metabolomics and PD-1/PD-L1 expression for early prediction of immunotherapy efficacy in advanced liver cancer.Scientific reports · 2026Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
76 authors.
Ignacio MeleroClínica Universidad de Navarra, CIMA, IDISNA and CIBERONC, Pamplona, Spain. imelero@unav.es.ORCID 0000-0002-1360-348X
Maria de Miguel LukenSTART Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain.
Guillermo de VelascoMedical Oncology Department, Hospital 12 de Octubre, Madrid, Spain.
Elena GarraldaVall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Barcelona, Spain.ORCID 0000-0002-4412-7842
Juan Martín-LiberalMedical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Spain.
Markus JoergerDepartment of Medical Oncology & Hematology, Cantonal Hospital, St Gallen, Switzerland.
Guzman AlonsoNEXT Oncology Phase I Unit/IOB - Hospital Quirónsalud Barcelona, Barcelona, Spain.
Maria-Elisabeth GoebelerMedizinische Klinik 2, Early Clinical Trial Unit, University Hospital Würzburg, Würzburg, Germany.
Martin SchulerWest German Cancer Center, Department of Medical Oncology, University Hospital Essen, Essen, Germany.ORCID 0000-0002-2166-3394
David KönigDepartment of Medical Oncology, University Hospital Basel, Basel, Switzerland.
Reinhard DummerDepartment of Dermatology, University Hospital Zurich, Zurich, Switzerland.ORCID 0000-0002-2279-6906
Maria ReigInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) & Liver Oncology Unit, Liver Unit, Hospital Clínic, Barcelona, Spain.
Maria-Esperanza Rodriguez RuizDepartment of Immunology and Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
Emiliano CalvoSTART Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain.ORCID 0000-0003-4921-829X
Jorge Esteban-VillarrubiaMedical Oncology Department, Hospital 12 de Octubre, Madrid, Spain.ORCID 0000-0002-2547-016X
Arjun OberoiVall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Paula SabatMedical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Spain.ORCID 0009-0003-1630-7453
Juan José Soto-CastilloMedical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Spain.ORCID 0000-0001-9630-4233
Kira-Lee KosterDepartment of Medical Oncology & Hematology, Cantonal Hospital, St Gallen, Switzerland.ORCID 0000-0002-6549-8124
Omar SaavedraNEXT Oncology Phase I Unit/IOB - Hospital Quirónsalud Barcelona, Barcelona, Spain.
Cyrus SayehliMedizinische Klinik 2, Early Clinical Trial Unit, University Hospital Würzburg, Würzburg, Germany.
Tanja GromkeWest German Cancer Center, Department of Medical Oncology, University Hospital Essen, Essen, Germany.ORCID 0009-0005-1373-0840
Heinz LäubliDepartment of Medical Oncology, University Hospital Basel, Basel, Switzerland.
Egle RamelyteDepartment of Dermatology, University Hospital Zurich, Zurich, Switzerland.
Marta FortunyInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) & Liver Oncology Unit, Liver Unit, Hospital Clínic, Barcelona, Spain.
Ana Landa-MagdalenaDepartment of Immunology and Oncology, Clínica Universidad de Navarra, Pamplona, Spain.ORCID 0000-0001-9352-4329
Irene MorenoSTART Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain.ORCID 0000-0001-5027-6388
Javier Torres-JiménezMedical Oncology Department, Hospital 12 de Octubre, Madrid, Spain.ORCID 0000-0001-9023-4529
Alberto Hernando-CalvoVall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Dagmar HessDepartment of Medical Oncology & Hematology, Cantonal Hospital, St Gallen, Switzerland.
Fabricio RaccaNEXT Oncology Phase I Unit/IOB - Hospital Quirónsalud Barcelona, Barcelona, Spain.
Heike RichlyWest German Cancer Center, Department of Medical Oncology, University Hospital Essen, Essen, Germany.
Andreas M SchmittDepartment of Medical Oncology, University Hospital Basel, Basel, Switzerland.ORCID 0000-0002-9568-8164
Corinne EggenschwilerDepartment of Dermatology, University Hospital Zurich, Zurich, Switzerland.
Marco Sanduzzi-ZamparelliInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) & Liver Oncology Unit, Liver Unit, Hospital Clínic, Barcelona, Spain.
Anna Vilalta-LacarraDepartment of Immunology and Oncology, Clínica Universidad de Navarra, Pamplona, Spain.ORCID 0000-0002-4787-5176
Jörg TrojanDepartment of Gastroenterology, Hepatology and Endocrinology, University Hospital Frankfurt, Frankfurt, Germany.ORCID 0000-0001-9414-378X
Christine KochDepartment of Gastroenterology, Hepatology and Endocrinology, University Hospital Frankfurt, Frankfurt, Germany.
Peter R GalleDepartment of Internal Medicine I, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Friedrich FoersterDepartment of Internal Medicine I, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Zlatko TrajanoskiInstitute of Bioinformatics, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0000-0002-0636-7351
Hubert HacklInstitute of Bioinformatics, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0000-0003-4055-3841
Falk GogollaInstitute of Bioinformatics, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0000-0001-9329-0294
Florestan J KollDepartment of Urology, Hospital of the Goethe University Frankfurt, Frankfurt am Main, Germany.ORCID 0000-0001-7828-3950
Peter WildSenckenberg Institute of Pathology, University Hospital Frankfurt, Frankfurt am Main, Germany.
Felix Kyoung Hwan ChunDepartment of Urology, Hospital of the Goethe University Frankfurt, Frankfurt am Main, Germany.
Henning ReisSenckenberg Institute of Pathology, University Hospital Frankfurt, Frankfurt am Main, Germany.
Peter LloydKinDyn Consulting, Warnham, UK.
Matthias MachacekLYO-X AG, Basel, Switzerland.ORCID 0000-0003-0541-2365
Thomas F GajewskiThe University of Chicago Medical Center, Chicago, IL, USA.
Wolf H FridmanCentre de Recherche des Cordeliers, INSERM U1138, Sorbonne Université, Université Paris Cité, Paris, France.ORCID 0000-0002-1332-0973
Alexander M M EggermontUniversity Medical Center Utrecht and Princess Máxima Center, Utrecht, The Netherlands.
Ralf BargouComprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany.ORCID 0000-0002-1221-7421
Sandra SchönigerDiscovery Life Sciences Biomarker Services, Kassel, Germany.
Josef RüschoffDiscovery Life Sciences Biomarker Services, Kassel, Germany.
Anastasiia TereshchenkoDiscovery Life Sciences Biomarker Services, Kassel, Germany.
Carina ZinkMetronomia Clinical Research, Munich, Germany.
Antonio da Silvada Silva Consulting Services, Munich, Germany.
Felix S LichteneggerCatalYm, Munich, Germany.
Julia AkdemirCatalYm, Munich, Germany.
Manfred RüdigerCatalYm, Munich, Germany.
Phil L'HuillierCatalYm, Munich, Germany.
Aradhana DuttaCatalYm, Munich, Germany.
Markus HaakeCatalYm, Munich, Germany.ORCID 0009-0008-3353-7919
Alexandra AuckenthalerCatalYm, Munich, Germany.
Ana GjorgjioskaCatalYm, Munich, Germany.ORCID 0009-0002-0886-0841
Bernhard RösslerCatalYm, Munich, Germany.ORCID 0009-0007-3347-4973
Frank HermannCatalYm, Munich, Germany.
Mara LiebigCatalYm, Munich, Germany.
Daniela ReichhardtCatalYm, Munich, Germany.
Christine Schuberth-WagnerCatalYm, Munich, Germany.
Jörg WischhusenDepartment of Gynecology, University Hospital Würzburg, Würzburg, Germany.
Petra FettesCatalYm, Munich, Germany.
Marlene AuerCatalYm, Munich, Germany.ORCID 0009-0005-1770-413X
Kathrin KlarCatalYm, Munich, Germany.ORCID 0000-0002-4808-8852
Eugen LeoCatalYm, Munich, Germany. eugen.leo@catalym.com.ORCID 0009-0004-4480-9351
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer immunotherapies with antibodies blocking immune checkpoint molecules are clinically active across multiple cancer entities and have markedly improved cancer treatment
Indexed as
Antibodies, NeutralizingB7-H1 AntigenDrug Resistance, NeoplasmGrowth Differentiation Factor 15Immune Checkpoint InhibitorsNeoplasmsProgrammed Cell Death 1 ReceptorFemaleHumansLung NeoplasmsMaleMiddle AgedNivolumabTumor MicroenvironmentAntibodies, NeutralizingB7-H1 AntigenCD274 protein, humanGDF15 protein, humanGrowth Differentiation Factor 15Immune Checkpoint InhibitorsNivolumabPDCD1 protein, humanProgrammed Cell Death 1 Receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.